ライフサイエンスコーパス: radiation dosimetry

1 (64)Cu-FBP8 administration to estimate human radiation dosimetry.

2 th (18)F-FPEB, we performed studies of human radiation dosimetry.

3 alternative with improved image quality and radiation dosimetry.

4 easure their comparative biodistribution and radiation dosimetry.

5 on, tissue iNOS levels, and calculated human radiation dosimetry.

6 al assessments of pharmacokinetics and organ radiation dosimetry.

7 1 provided good imaging of NHL and favorable radiation dosimetry.

8 fter infusion to assess pharmacokinetics and radiation dosimetry.

9 a is a general approach for medical internal radiation dosimetry.

10 entation; 2) 10 days of personal ultraviolet radiation dosimetry; 3) a sun exposure and physical acti

11 re conducted to evaluate biodistribution and radiation dosimetry after intravenous injection of (18)F

12 ated in 2 studies: in the first study, human radiation dosimetry and biodistribution of (11)C-metform

13 erformed over 48 h for calculation of tissue radiation dosimetry and for evaluation of clinical safet

14 Understanding radiation dosimetry and its potential for deleterious he

15 uorodeoxyglucose (FDG), to contribute to its radiation dosimetry and to define a suitable proxy for a

16 mical parameters before and after treatment, radiation dosimetry, and complications were recorded.

17 Safety, biodistribution, radiation dosimetry, and the most appropriate imaging ti

18 Data on chemical stability, radiation dosimetry, and toxicity of FCH were obtained.

19 Radiation dosimetry assessment was performed using pharm

20 tives of this phase I study were to evaluate radiation dosimetry, biodistribution, human safety, tole

21 human experience with (18)F-FEOBV, including radiation dosimetry, biodistribution, tolerability and s

22 Radiation dosimetry calculations indicate that there is

23 The whole-body and individual organ radiation dosimetry characteristics and pharmacologic sa

24 The 188Re(Sn)HEDP has biodistribution and radiation dosimetry characteristics that are similar to

25 Human normal-organ kinetics, radiation dosimetry, clinical safety, and imaging effica

26 F-FETrp tumoral uptake, biodistribution, and radiation dosimetry data provide strong preclinical evid

27 Clinical data and HP axis radiation dosimetry data were obtained from 88 eligible

28 were acquired over 6 h for (18)F-MNI-659 and radiation dosimetry estimated with OLINDA.

29 Revised radiation dosimetry estimates for 201Tl-thallous chlorid

30 Radiation dosimetry estimates for 90Y-J591 calculated on

31 Radiation dosimetry estimates indicate that more than 40

32 Radiation dosimetry estimates indicated that the dose-li

33 Radiation dosimetry estimates were calculated using avai

34 Radiation dosimetry estimates were calculated using the

35 The (18)F-PEG(6)-IPQA pharmacokinetic and radiation dosimetry estimates were determined using volu

36 Whole-body PET images were acquired for radiation dosimetry estimates.

37 conventional formulations, and the predicted radiation dosimetry estimations for some organs varied s

38 The radiation dosimetry for (11)C-CNS5161 for a standard sin

39 The radiation dosimetry for (111)In and (177)Lu compared fav

40 The radiation dosimetry for (18)F-FETrp determined from the

41 We herein assess the cytotoxicity and radiation dosimetry for (68)Ga-NOTA-UBI and a first-in-h

42 aim of this study was to derive PET/CT-based radiation dosimetry for (89)Zr-cetuximab, with special e

43 macokinetic data and 90Y physical constants, radiation dosimetry for 90Y-21T-BAD-Lym-1 was determined

44 This article reviews radiation dosimetry for radiopharmaceuticals and also CT

45 dy was to determine the pharmacokinetics and radiation dosimetry for the initial 131I-Lym-1 therapy d

46 We estimated the radiation dosimetry for this tracer from data gathered i

47 We estimated the radiation dosimetry for this tracer using data obtained

48 whole-body biodistribution and estimate the radiation dosimetry from (11)C-CURB scans in humans.

49 Radiation dosimetry in "sensitive" populations, includin

50 ion of 99mTc-labeled anti-SSEA-1 and perform radiation dosimetry in 10 healthy human volunteers.

51 was evaluated for distribution, binding, and radiation dosimetry in a healthy cynomolgus monkey.

52 as to measure its whole-body biokinetics and radiation dosimetry in healthy human volunteers.

53 its whole-body biokinetics and estimate its radiation dosimetry in healthy human volunteers.

54 This study was designed to evaluate the radiation dosimetry in human subjects for a new radiopha

55 y was to assess safety, biodistribution, and radiation dosimetry in humans for the highly selective s

56 background signal, biosafety, and acceptable radiation dosimetry in humans.

57 onuclides and the need for greater accuracy, radiation dosimetry in nuclear medicine is evolving from

58 rt the safety, biodistribution, and internal radiation dosimetry, in humans with thyroid cancer, of (

59 Laboratory reporting of radiation dosimetry is a critical component of creating

60 s and assessed the feasibility of generating radiation dosimetry maps in liver regions with high and

61 paclitaxel PET/CT tumor imaging and provides radiation dosimetry measurements in humans.

62 e calculational ease of the Medical Internal Radiation Dosimetry (MIRD) system with the additional in

63 ole-body PET/CT was used to characterize the radiation dosimetry of (11)C-DPA-713, a specific PET lig

64 , we measured the whole-body biokinetics and radiation dosimetry of (123)I-IMPY in AD patients and co

65 describe the initial clinical experience and radiation dosimetry of (18)F-DCFBC in men with metastati

66 The radiation dosimetry of (18)F-FBAU was evaluated using th

67 nteers underwent imaging to verify the human radiation dosimetry of (18)F-FTT.

68 cokinetics, biodistribution, metabolism, and radiation dosimetry of (18)F-PEG(6)-IPQA in nonhuman pri

69 evaluate the biodistribution, kinetics, and radiation dosimetry of (64)CuCl2 in humans and to assess

70 iodistribution, kinetics of the lesions, and radiation dosimetry of (64)CuCl2 were evaluated.

71 measure the biodistribution and estimate the radiation dosimetry of (68)Ga-ABY-025 for 2 different pe

72 lism, pharmacokinetics, biodistribution, and radiation dosimetry of (68)Ga-bombesin antagonist (68)Ga

73 The whole-body distribution and radiation dosimetry of (68)Ga-pentixafor were evaluated.

74 Whole-body radiation dosimetry of 11C-raclopride was performed in h

75 This study evaluates the kinetics and radiation dosimetry of 18F-FCH using murine and human bi

76 etics for 67Cu and 64Cu was assumed, and the radiation dosimetry of 64Cu was assessed using quantitat

77 ding 131I-labeled monoclonal antibodies, the radiation dosimetry of 90Y-2-iminothiolane-2-[p-(bromoac

78 The radiation dosimetry of 90Y-J591 was estimated based on b

79 This study assessed the radiation dosimetry of 99mTc-labeled ethylene dicysteine

80 investigated the whole-body distribution and radiation dosimetry of both radiotracers in humans.

81 The tau values for radiation dosimetry of FDG in the heart, lungs, liver an

82 The present study sought to measure the radiation dosimetry of IPT in seven healthy human volunt

83 man safety, whole-organ biodistribution, and radiation dosimetry of LMI1195 were evaluated in a phase

84 Whole-body distribution and radiation dosimetry of this new probe were evaluated.

85 From the radiation dosimetry perspective, the apoptosis imaging a

86 Radiation dosimetry PET/CT experiments indicated that mo

87 The estimates of radiation dosimetry, pharmacokinetic parameters, and saf

88 Therefore, from a radiation dosimetry point of view, HD is preferred for P

89 Therefore, from a radiation dosimetry point of view, there is no preferenc

90 The findings suggest that the radiation dosimetry profile for this new infection imagi

91 uptake reflects PARP expression and that its radiation dosimetry profile is compatible with those of

92 rt the safety, biodistribution, and internal radiation dosimetry profiles of (18)F-D4-FCH in 8 health

93 rt the safety, biodistribution, and internal radiation dosimetry profiles of (18)F-ICMT-11 in 8 healt

94 sed in conjunction with the Medical Internal Radiation Dosimetry schema to: estimate absorbed doses i

95 indicated that both disposition kinetics and radiation dosimetry support its clinical use for imaging

96 In cancer therapy, radiation dosimetry supports treatment planning, dose-re

97 Radiation dosimetry to adult reproductive organs was les

98 Radiation dosimetry to the HP axis was associated only w

99 d after infusion to assess pharmacokinetics, radiation dosimetry, toxicity and tumor regression.

100 Radiation dosimetry was acceptable, with effective doses

101 Radiation dosimetry was assessed using the MIRD method.

102 tative organ distribution was determined and radiation dosimetry was calculated.

103 In advance of human studies, radiation dosimetry was determined in nonhuman primates.

104 Radiation dosimetry was estimated by whole-body PET of a

105 Radiation dosimetry was favorable (effective dose, 5.2 m

106 Radiation dosimetry was performed to estimate radiation

107 Otherwise, radiation dosimetry was, on average, remarkably similar

108 The biodistribution and radiation dosimetry were assessed by serial whole-body P

109 Additionally, toxicity and radiation dosimetry were assessed.

110 the dosimetry group, the biodistribution and radiation dosimetry were calculated using whole-body PET

111 During therapy, pharmacokinetics and radiation dosimetry were evaluated.

112 based biodistribution, pharmacokinetics, and radiation dosimetry were performed on nonhuman primates.

113 Pharmacokinetics and radiation dosimetry were, on average, remarkably similar

114 (11)C-sarcosine showed a favorable radiation dosimetry with an effective dose estimate of 0